Covid-19 roundup: Eli Lilly retrofits RVs for first-of-its-kind antibody trial with NIH; Amgen, AbbVie, Takeda team on a drug
Eli Lilly and the NIH are about to start a first-of-its-kind trial that researchers and developers have talked about for months as a way of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
